Newsroom
July 1, 2021
Dr. Dimpy P. Shah, Population Health Sciences/ Mays Cancer Center, was included within a story of the San Luis Obispo Tribune addressing her research in which 94% of the 131 patients in the study produced antibodies three to four weeks after full vaccination, most of which had solid cancers as opposed to cancers in the […]
July 1, 2021
Dr. Dimpy P. Shah, Population Health Sciences/Mays Cancer Center, was included within a story in Yahoo addressing her research in which 94% of the 131 patients in the study produced antibodies three to four weeks after full vaccination, most of which had solid cancers as opposed to cancers in the blood. Read story
July 1, 2021
In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact that a small group of the patients exhibited no response raised questions about how their protection against the virus will be addressed moving forward.
June 30, 2021
Small subsets of high-risk patients produce few or no antibodies, however. Contact: Will Sansom, (210) 567-2579, sansom@uthscsa.edu SAN ANTONIO (June 30, 2021) — In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact […]
June 23, 2021
The Mays Cancer Center, home to UT Health San Antonio MD Anderson, was named a founding partner of the Advancing Inclusive Research® Site Alliance.
June 23, 2021
Media contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (June 23, 2021) – The Mays Cancer Center, home to UT Health San Antonio MD Anderson, today was announced as a founding partner of the Advancing Inclusive Research® Site Alliance. This coalition of clinical research sites will partner with Genentech, a member of the Roche Group, to […]
